Abstract Number: 2594 • 2018 ACR/ARHP Annual Meeting
Median Time to Pain Improvement in Patients with Psoriatic Arthritis Treated with Tofacitinib
Background/Purpose: Pain is a core domain of psoriatic arthritis (PsA).1 Rapid, sustained pain reduction is a priority for patients (pts) and physicians when choosing treatment.…Abstract Number: 424 • 2017 ACR/ARHP Annual Meeting
Re-Establishment of Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in Rheumatoid Arthritis Patients after Temporary Discontinuation
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assessed tofacitinib efficacy and safety after temporary discontinuation and…Abstract Number: 596 • 2017 ACR/ARHP Annual Meeting
Effect of Tofacitinib on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis: Results from 2 Phase 3 Studies
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Safety and efficacy were investigated in 2 Phase…Abstract Number: 613 • 2017 ACR/ARHP Annual Meeting
Effect of Tofacitinib on Efficacy and Patient-Reported Outcomes in Psoriasis Patients with Baseline Psoriatic Arthritis: A Pooled Analysis of 2 Phase 3 Studies
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Up to 42% of patients (pts) with psoriasis…Abstract Number: 619 • 2017 ACR/ARHP Annual Meeting
Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of psoriatic arthritis (PsA). We examined tofacitinib efficacy in patients (pts) with active…Abstract Number: 620 • 2017 ACR/ARHP Annual Meeting
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open‑Label, Long-Term Extension Study
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for psoriatic arthritis (PsA). Interim data up to January 2017 (database not locked) report the…Abstract Number: 623 • 2017 ACR/ARHP Annual Meeting
Tofacitinib Improves Composite Endpoint Measures of Disease in Patients with Psoriatic Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). PsA is a heterogeneous disease and composite endpoints…Abstract Number: 880 • 2017 ACR/ARHP Annual Meeting
Tofacitinib Treatment in Patients with Psoriatic Arthritis and Rates of Radiologic Progression According to Baseline CRP Levels: Results from a Phase 3 Clinical Study
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Here, we evaluate radiographic progression in PsA patients…Abstract Number: 884 • 2017 ACR/ARHP Annual Meeting
Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients with Psoriatic Arthritis: An Integrated Analysis across Phase 3 and Long-Term Extension Studies
Background/Purpose: Cardiovascular (CV) disease and cardiometabolic syndrome are common comorbidities/causes of mortality in patients (pts) with psoriatic arthritis (PsA). Tofacitinib is an oral Janus kinase…Abstract Number: 10L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of PsA. In this first study of tofacitinib in patients (pts) with active…Abstract Number: 1647 • 2016 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 8 Years
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The objective of this analysis was to report tofacitinib safety and tolerability…Abstract Number: 2983 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, or Adalimumab in Patients with Active Psoriatic Arthritis and an Inadequate Response to Conventional Synthetic Dmards: A Randomized, Placebo‑Controlled, Phase 3 Trial
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of psoriatic arthritis (PsA). This study evaluated tofacitinib efficacy and safety vs placebo…Abstract Number: 1645 • 2015 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report tofacitinib safety, tolerability, and clinical response over 84 months…Abstract Number: 2742 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib Monotherapy Versus Combination Therapy in a Latin American Subpopulation of Patients with Rheumatoid Arthritis: A Pooled Phase 3 Analysis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post-hoc pooled analysis was designed to assess the efficacy and safety…Abstract Number: 1639 • 2015 ACR/ARHP Annual Meeting
Clinical Outcomes for Rheumatoid Arthritis Patients Receiving Tofacitinib Monotherapy in the Open-Label Long-Term Extension over 6 Years
Background/Purpose: Treatment options delivering sustained efficacy when given as monotherapy in RA are limited.1 Tofacitinib is an oral Janus kinase inhibitor for the treatment of…
ACR Meeting Abstracts